Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1Lung Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cisplatin 6Platinum 5Pemetrexed 51,2-diaminocyclohexaneplatinum II citrate 5pembrolizumab 4atezolizumab 2Radiotherapy 2Radiation 2Nivolumab 2Ipilimumab 2Gemcitabine 2Cyclophosphamide 2Carboplatin 2tremelimumab 1methoxyamine 1fludarabine 1decitabine and cedazuridine drug combination 1cediranib 1anetumab ravtansine 1aldesleukin 1Trioxsalen 1Tissue Banks 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Phototherapy 1Photochemotherapy 1Pharmacogenomic Testing 1Pharmaceutical Preparations 1Interleukin-2 1Influenza Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × methoxyamine × 90 days × Clear all
NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
30 enrolled 15 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡